Servier Oncology R&D has announced the appointment of Peter Adamson, MD, FASCO, as the new leader of its oncology clinical development team. Adamson is a globally recognized physician-scientist and executive in oncology drug development and clinical pharmacology.
Adamson, a Professor Emeritus at the University of Pennsylvania, has extensive experience leading Phase 1–3 clinical trials and R&D programs across academia, industry, and government. Prior to joining Servier, he served as Global Head of Oncology Development at Sanofi, where he managed over 15 global development teams working on early- and late-stage assets, including antibody-drug conjugates, cell and immune therapies, and cytokines. He also contributed to business development efforts across the U.S., Europe, and China and supported the integration of four acquisitions. Under his leadership, the drug Sarclisa received six global approvals.
In academia, Adamson was Chair and CEO of the Children’s Oncology Group (COG), launching Project:EveryChild, the world’s largest ongoing pediatric cancer research initiative. At the Children’s Hospital of Philadelphia and the University of Pennsylvania, he founded a cross-disciplinary drug development division, co-led an NIH-funded translational science center, and developed the Rolling Six phase 1 trial design.
Appointed by President Barack Obama to the National Cancer Advisory Board, Adamson also served on the Cancer Moonshot Blue Ribbon Panel. He has advised more than 15 cancer foundations and has played a key role in U.S. childhood cancer policy development.
Adamson holds an MD from Cornell University Medical College and a BA in Chemistry from Wesleyan University. He completed his pediatric residency at the Children’s Hospital of Philadelphia and a fellowship in Pediatric Hematology/Oncology at the National Cancer Institute.
Leave a Reply